An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

January 15, 2023

Study Completion Date

January 15, 2023

Conditions
Metastatic Colorectal Cancer
Interventions
OTHER

Retrospective patient chart review

Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).

Trial Locations (1)

07981

Many locations, Whippany

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY